Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (£272m) over five years due to the United States' demand for confidential data.
This move came to light after a official document from December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesman later explained that the US was requesting genetic material for research and commercial gain but was not willing to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for further talks to secure a agreement agreeable to both sides so the nation's critical HIV programme can be sustained.
Wider Implications
This development follows a similar situation in Kenya, where a court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and accountability.
As per reports, Sixteen African countries have to date agreed to these new agreements, representing over $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information for a long time, without any equivalent promise of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would provide the raw materials for scientific discovery with no certainty that the end products would be accessible to our population if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining structures previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further discussions with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and dignity of each country."
Medical Community Response
A leading public health body said it recognised the government's concerns, but urged that negotiations must proceed since much of the nation's HIV programmes depended on external financing.
"Where technical issues arise, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The halted deal underscores the ongoing debate between accepting crucial international aid and protecting a country's data in an increasingly interconnected world.